Anna Bogstedt

BioPharmaceuticals R&D
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naive Patients.

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naive Patients.

Journal: Circulation

Published: May 15, 2026

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients.

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients.

Journal: Circulation

Published: May 15, 2026

MEDI1814 selectively reduces free Aβ42 in cerebrospinal fluid of non-clinical species and Alzheimer's disease patients.

MEDI1814 selectively reduces free Aβ42 in cerebrospinal fluid of non-clinical species and Alzheimer's disease patients.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: April 03, 2024

Vascular endothelial growth factor-D plasma levels and VEGFD genetic variants are independently associated with outcomes in patients with cardiovascular disease.

Vascular endothelial growth factor-D plasma levels and VEGFD genetic variants are independently associated with outcomes in patients with cardiovascular disease.

Journal: Cardiovascular research

Published: June 19, 2022

Urine APOL1 Isoforms Reflect Plasma-Derived Liver-Synthesized Proteins.

Urine APOL1 Isoforms Reflect Plasma-Derived Liver-Synthesized Proteins.

Journal: Journal of the American Society of Nephrology : JASN

Published: March 29, 2021

Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo.

Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo.

Journal: Neurobiology of disease

Published: July 19, 2019

Differential Effect of APOE Alleles on Brain Glucose Metabolism in Targeted Replacement Mice: An [18F]FDG-μPET Study.

Differential Effect of APOE Alleles on Brain Glucose Metabolism in Targeted Replacement Mice: An [18F]FDG-μPET Study.

Journal: Journal of Alzheimer's disease reports

Published: November 28, 2018

Synaptic proteins in CSF relate to Parkinson's disease stage markers.

Synaptic proteins in CSF relate to Parkinson's disease stage markers.

Journal: NPJ Parkinson's disease

Published: October 07, 2016

AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics.

AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics.

Journal: Journal of Alzheimer's disease : JAD

Published: February 19, 2016

Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia.

Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: December 12, 2015

Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies.

Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies.

Journal: Journal of Alzheimer's disease : JAD

Published: September 25, 2015

Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β.

Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β.

Journal: Brain : a journal of neurology

Published: November 22, 2013

Showing 1-12 of 15

Last Updated: 09/26/2026